McBroom & Associates LLC Lowers Holdings in Zoetis Inc. $ZTS

Key Points

• McBroom & Associates LLC cut its Zoetis stake by 72.8% in Q4, selling 21,006 shares and leaving 7,849 shares valued at $988,000.
• Zoetis beat quarterly estimates with $1.48 EPS (vs. $1.40) and $2.39B revenue, and gave FY2026 guidance of 7.00–7.10 EPS.
• Analysts hold a consensus Hold rating with an average price target of $152.91 while the stock traded near $117.83, implying material upside to the target.

McBroom & Associates LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 72.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,849 shares of the company's stock after selling 21,006 shares during the quarter. McBroom & Associates LLC's holdings in Zoetis were worth $988,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ZTS. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 1.0% in the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company's stock valued at $6,190,326,000 after acquiring an additional 419,777 shares in the last quarter. Nordea Investment Management AB raised its holdings in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock worth $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Zoetis by 14.6% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company's stock valued at $631,046,000 after purchasing an additional 550,859 shares during the period. Alliancebernstein L.P. lifted its position in Zoetis by 13.3% in the third quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company's stock valued at $620,595,000 after purchasing an additional 496,320 shares during the period. Finally, Fundsmith LLP boosted its holdings in Zoetis by 25.3% in the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company's stock valued at $528,966,000 after purchasing an additional 730,300 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. Weiss Ratings cut Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Barclays started coverage on Zoetis in a report on Monday, December 8th. They set an "equal weight" rating and a $136.00 price objective on the stock. William Blair reiterated an "outperform" rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Piper Sandler reissued a "neutral" rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $152.91.

Zoetis Trading Down 0.1%

Shares of Zoetis stock opened at $117.83 on Friday. The company has a 50-day moving average of $122.71 and a two-hundred day moving average of $128.09. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market cap of $49.74 billion, a PE ratio of 19.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis's payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.